Thymoquinone Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱
Features: Anti-oxidant, anti-tumor
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Label Primary Effect Notes / Cancer Relevance Ref
1 Reactive oxygen species (ROS) ↑ ROS Driver Upstream cytotoxic trigger Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts (ref)
2 Glutathione (GSH) redox buffering ↓ GSH Driver Redox-collapse amplification Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Driver Mitochondrial dysfunction (MOMP axis) Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death) (ref)
4 Intrinsic apoptosis (caspase-9 → caspase-3; PARP) ↑ caspases / ↑ apoptosis Driver Execution-phase cell death Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway (ref)
5 NF-κB signaling ↓ NF-κB activity Secondary Reduced pro-survival / inflammatory transcription Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support) (ref)
6 STAT3 signaling ↓ p-STAT3 / ↓ STAT3 activation Secondary Reduced survival/proliferation signaling Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts (ref)
7 NRF2 antioxidant-response axis (NRF2/HO-1 program) ↑ NRF2 pathway (often as stress-response) Adaptive Cellular antioxidant counter-response In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress (ref)
8 HIF-1α hypoxia signaling ↓ HIF-1α protein / ↓ HIF-1α program Adaptive Loss of hypoxia survival signaling Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia (ref)
9 Glycolysis / Warburg output (hypoxia-linked) ↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism) Phenotypic Metabolic suppression In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation (ref)  |  (ref)


Scientific Papers found: Click to Expand⟱
2102- TQ,    A review on therapeutic potential of Nigella sativa: A miracle herb
- Review, Var, NA
angioG↓, NF-kB↓, PPARγ↓, Bcl-2↓, Bcl-xL↓, MUC4↓, cJun↑, p38↑, P21↑, HDAC↓, *radioP↑, hepatoP↑,
1931- TQ,  doxoR,    Thymoquinone enhances the anticancer activity of doxorubicin against adult T-cell leukemia in vitro and in vivo through ROS-dependent mechanisms
- in-vivo, AML, NA
ChemoSen↑, tumCV↓, TumCCA↑, ROS↑, MMP↓, eff↓, TumVol↓, eff↑, Ki-67↓,
1932- TQ,    Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis
- Review, Var, NA
ROS↑,
1933- TQ,    Thymoquinone: potential cure for inflammatory disorders and cancer
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCCA↑, ROS↑, angioG↓, Apoptosis↑, Casp↑, ChemoSen↑, eff↝,
1934- TQ,    Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species
- in-vitro, Pca, PC3 - in-vitro, Pca, C4-2B
ROS↑, GSH↓, eff↓, AR↓,
1935- TQ,    Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis
- Review, OS, NA
Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, ROS↑, P53↑, Twist↓, E-cadherin↑, N-cadherin↓, NF-kB↓, IL8↓, XIAP↓, Bcl-2↓, STAT3↓, MAPK↓, PI3K↓, Akt↓, ERK↓, MMP2↓, MMP9↓, *ROS↓, HO-1↑, selectivity↑, TumCG↓,
1936- TQ,    Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line
- in-vitro, Ovarian, CaOV3 - in-vitro, Nor, WRL68
selectivity↑, TumCP↓, MMP↓, Bcl-2↓, BAX↑, ROS↑,
1937- TQ,    Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models
- in-vitro, Wounds, 3T3
*ROS↓, *antiOx↓, *BioAv↓, *BioAv↑, *NO↑, *SOD↑, *GPx↑, *Catalase↑,
2083- TQ,    Thymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro
- in-vitro, GC, HGC27 - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vivo, NA, NA
p‑STAT3↓, JAK2↓, c-Src↓, Bcl-2↓, cycD1/CCND1↓, survivin↓, VEGF↓, Casp3?, Casp7?, Casp9?, *toxicity∅, TumVol↓,
2128- TQ,    Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo
- in-vivo, Nor, NA
*COX2/PTGS2↓, *NF-kB↓, *p‑Akt↓, *p‑cJun↓, *p‑p38↓, *HO-1↑, *NADPH↑, *GSTA1↑, *antiOx↑, *Inflam↓, *NQO1↑, *GCLC↑, *GSTA1↑,
2120- TQ,    Thymoquinone induces apoptosis of human epidermoid carcinoma A431 cells through ROS-mediated suppression of STAT3
- in-vitro, Melanoma, A431
ROS↑, Apoptosis↑, P53↑, BAX↑, MDM2↓, Bcl-2↓, Bcl-xL↓, Casp9↑, Casp7↑, Casp3↑, STAT3↓, cycD1/CCND1↓, survivin↓, eff↓,
2121- TQ,    Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
p‑p38↑, ROS↑, TumCP↓, ChemoSen↑, XIAP↓, survivin↓, Bcl-xL↓, Bcl-2↓, Ki-67↓, *Catalase↑, *SOD↑, *GSH↑, hepatoP↑, p‑MAPK↑, JNK↓, eff↓,
2122- TQ,    Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer
- Review, Var, NA
ChemoSen↓, *ROS↓, *GSH↑, RenoP↑, hepatoP↑, COX2/PTGS2↓, NF-kB↓, chemoPv↑, neuroP↑, TumCCA↑, P21↑, p27/CDKN1B↑, ROS↑, DNAdam↑, MUC4↓,
2123- TQ,    Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion lymphoma
- in-vitro, lymphoma, PEL
Akt↓, ROS↑, BAX↓, MMP↓, Cyt‑c↑, Synergy↑, Casp9↑, Casp3↑, cl‑PARP↑, DR5↑,
2124- TQ,    Thymoquinone: an emerging natural drug with a wide range of medical applications
- Review, Var, NA
hepatoP↑, Bax:Bcl2↑, cycD1/CCND1↓, P21↑, TRAIL↑, P53↑, TumCCA↑, hepatoP↑, *ALAT↓, *AST↓, *MDA↓, *GSSG↓, *COX2/PTGS2↓, *lipid-P↓, PPARγ↑, p38↑, ROS↑, ChemoSen↑, selectivity↑, selectivity↑, *MDA↓, *SOD↑, *antiAll↑,
2125- TQ,    Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
- in-vitro, RCC, RCC4 - in-vitro, RCC, Caki-1
Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX/CA9↓, PDK1 / PDPK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,
2126- TQ,    Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway
- Review, Nor, NA
*antiOx↑, *Bacteria↓, *RenoP↑, *hepatoP↑, *neuroP↑, *Inflam↓, *Keap1↓, *NRF2↑, *other↝,
2127- TQ,    Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways
- Review, GBM, NA
chemoP↑, ChemoSen↑, BioAv↑, PTEN↑, PI3K↓, Akt↓, TumCCA↓, NF-kB↓, p‑Akt↓, p65↓, XIAP↓, Bcl-2↓, COX2/PTGS2↓, VEGF↓, mTOR↓, RAS↓, Raf↓, MEK↓, ERK↓, MMP2↓, MMP9↓, TumCMig↓, TumCI↓, Casp↑, cl‑PARP↑, ROS⇅, ROS↑, MMP↓, Synergy↑, Telomerase↓, DNAdam↑, Apoptosis↑, STAT3↓, RadioS↑,
2119- TQ,    Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant
- Review, Var, NA
*ROS↓, ROS↑, chemoP↑, RenoP↑, hepatoP↑, NLRP3↓, neuroP↑, NF-kB↓, P21↑, HDAC↓, Apoptosis↑, TumCP↓, GSH↓, GADD45A↑, GSK‐3β↑,
2129- TQ,  doxoR,    Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells
- in-vitro, BC, MCF7
ChemoSen↑, PTEN↑, p‑Akt↓, TumCCA↑, P53↑, P21↑, Apoptosis↑, MMP↓, Casp↑, cl‑PARP↑, Bax:Bcl2↑, eff↓, DNAdam↓, p‑γH2AX↑, ROS↑,
2130- TQ,    Thymoquinone Attenuates Brain Injury via an Anti-oxidative Pathway in a Status Epilepticus Rat Model
- in-vivo, Nor, NA
*eff↑, *memory↑, *NRF2↑, *HO-1↑, *SOD↑, *ROS↓,
2131- TQ,    Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway
- in-vitro, Stroke, NA - in-vivo, Nor, NA
*eff↑, *OS↑, *Inflam↓, *ROS↓, *NRF2↑, *HO-1↑,
2132- TQ,    Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis
- in-vivo, Nor, NA
*Weight∅, *antiOx↑, *lipid-P↓, *MMP7↓, *Casp3↓, *BAX↓, *TGF-β↓, *Diff↑, *NRF2↓, *HO-1↓, *NF-kB↓, *IκB↑,
2133- TQ,  CUR,  Cisplatin,    Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling
- in-vitro, Nor, HEK293 - in-vivo, NA, NA
*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,
2134- TQ,    Modulation of Nrf2/HO1 Pathway by Thymoquinone to Exert Protection Against Diazinon-induced Myocardial Infarction in Rats
- in-vivo, Nor, NA
*ALAT↓, *AST↓, *MDA↓, *ROS↓, *GSSG↓, *GSH↑, *VitE↑, *VitC↑, *NRF2↑, *HO-1↑, *NQO1↑, *SOD↑, *cardioP↑, *GSH/GSSG↑, *GPx↑,
2135- TQ,    Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets
- in-vitro, Nor, HaCaT
*HO-1↑, *NRF2↑, *e-ERK↑, *e-Akt↑, *AMPKα↑, *ROS⇅, *eff↓, *tumCV∅,
2136- TQ,    Nigella sativa and thymoquinone suppress cyclooxygenase-2 and oxidative stress in pancreatic tissue of streptozotocin-induced diabetic rats
- in-vivo, Nor, NA
*COX2/PTGS2↓, *lipid-P↓, *SOD↑, *ROS↓, *Inflam↓, *NF-kB↓,
2111- TQ,  MTX,    Effect of Nigella sativa (black seeds) against methotrexate-induced nephrotoxicity in mice
- in-vivo, Nor, NA
*RenoP↑, *GSH↑,
2103- TQ,    Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells
- in-vitro, PC, Hs766t - in-vitro, PC, MIA PaCa-2
MCP1/CCL2↓, TNF-α↓, IL1β↓, COX2/PTGS2↓, NF-kB↓, HDAC↓, P21↑,
2104- TQ,    The Potential Role of Nigella sativa Seed Oil as Epigenetic Therapy of Cancer
- in-vitro, BC, MCF7 - in-vitro, Cerv, HeLa
TumCP↓, Apoptosis↑, UHRF1↓, DNMT1↓, HDAC1↓, eff↝,
2105- TQ,    Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation
- in-vitro, PC, AsPC-1 - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, Hs766t - in-vivo, NA, NA
tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, P53↑, Bcl-2↓, P21↑, ac‑H4↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, TumVol↓,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,
2107- TQ,    Cytotoxicity of Nigella sativa seed oil and extract against human lung cancer cell line
- in-vitro, Lung, A549
tumCV↑,
2108- TQ,    Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa
- Review, Var, NA
HDAC↓, TumCCA↑, cycD1/CCND1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2/BIRC3↓, XIAP↓, survivin↓, COX2/PTGS2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,
2109- TQ,    Thymoquinone Induces Mitochondria-Mediated Apoptosis in Acute Lymphoblastic Leukaemia in Vitro
- in-vitro, AML, CEM
Apoptosis↓, Bcl-2↓, BAX↑, ROS↑, HSP70/HSPA5↑, Casp3↑, Casp8↑,
2110- TQ,    Nigella sativa seed oil suppresses cell proliferation and induces ROS dependent mitochondrial apoptosis through p53 pathway in hepatocellular carcinoma cells
- in-vitro, HCC, HepG2 - in-vitro, BC, MCF7 - in-vitro, Lung, A549 - in-vitro, Nor, HEK293
P53↑, lipid-P↑, GSH↓, ROS↑, MMP↓, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, tumCV↓, selectivity↑,
113- TQ,    Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
- vitro+vivo, Pca, C4-2B
HH↓, Shh↓, Gli1↓, CompStab↑, TumCP↓,
2112- TQ,    Crude flavonoid extract of the medicinal herb Nigella sativa inhibits proliferation and induces apoptosis in breastcancer cells
- in-vitro, BC, MCF7
Apoptosis↑, DNAdam↑, ROS↑, GSH↓, MMP↓, Casp3↑, Casp7↑, Casp9↑, Bax:Bcl2↑, P53↑, P21↑, cycD1/CCND1↓, GSSG↑, GSH/GSSG↓,
2113- TQ,    Potential role of Nigella sativa (NS) in abating oxidative stress-induced toxicity in rats: a possible protection mechanism
- in-vivo, Nor, NA
*antiOx↑, *RenoP↑, *hepatoP↑, *SOD↑, *GSH↑, *ROS↓, *lipid-P↓, ALAT↓, creat↓,
2114- TQ,    Anti-Aging Effect of Nigella Sativa Fixed Oil on D-Galactose-Induced Aging in Mice
- in-vivo, Nor, NA
*ALAT↓, *AST↓, *lipid-P↓, *GSH↑, *Bax:Bcl2↓, *proCasp3↓, *cl‑Casp3↓, *antiOx↑,
2115- TQ,    Protective effects of Nigella sativa on gamma radiation-induced jejunal mucosal damage in rats
- in-vivo, Nor, NA
*radioP↑, *MDA↓, *GSH↑,
2116- TQ,  Cisplatin,    Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver
- in-vivo, Nor, NA
*hepatoP↑, *antiOx↑, *ROS↓, ALAT↓, AST↓,
2117- TQ,    Effects of Nigella sativa L. on Lipid Peroxidation and Reduced Glutathione Levels in Erythrocytes of Broiler Chickens
- in-vivo, Nor, NA
*GSH↑, *ROS↓,
2118- TQ,  Rad,    In vivo radioprotective effects of Nigella sativa L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats
- in-vivo, Nor, NA
*ROS↓, RenoP↑, hepatoP↑,
7940- TQ,    Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation
- in-vivo, Asthma, NA
*Eos↓, *Th2↓, *IgE↓, *IgG1↓, *Inflam↓, *AirwayM↓, *IL4↓, *IL5↓, *IL13↓, *IFN-γ↑, *antiAll↑,
7941- TQ,    Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma
- in-vivo, Asthma, NA
*5LO↓, *LTB4↓, *LTC4↓, *Th2↓, *Eos↓, *Inflam↓, *antiAll↑,
7942- TQ,    Thymoquinone inhibits inflammation, neoangiogenesis and vascular remodeling in asthma mice
- in-vitro, Asthma, NA
*IL4↓, *IL5↓, *CD31/PECAM-1↓, *VEGFR2/KDR/Flk1↓, *PI3K↓, *Akt↓, *SLIT2↑, *Inflam↓, *VEGF↓, *antiAll↑,
8465- TQ,  docx,    Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells
- in-vitro, BC, NA
ChemoSen?, ROS↑, eff↓, Bcl-2↓, PI3K↓, AKT1↓, BAX↑, Casp9↑, PTEN↑,

Showing Research Papers: 101 to 148 of 148
Prev Page 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 148

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 5,   ARE/EpRE↑, 1,   Catalase↑, 3,   GCLM↑, 2,   GPx↑, 1,   GPx1⇅, 1,   GPx4↓, 1,   GSH↓, 6,   GSH↑, 3,   GSH/GSSG↓, 1,   GSR↑, 1,   GSSG↑, 2,   GSTs↑, 1,   H2O2↓, 2,   HO-1↑, 2,   lipid-P↑, 1,   MDA↑, 1,   NQO1↑, 2,   NRF2↓, 1,   NRF2↑, 6,   ROS↓, 4,   ROS↑, 41,   ROS⇅, 5,   SOD↑, 2,   SOD1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 1,   PDH↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 2,   ALAT↓, 2,   AMPK↑, 2,   ATP↓, 1,   i-ATP↓, 1,   CAIX/CA9↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   GSK‐3β↓, 2,   GSK‐3β↑, 2,   p‑GSK‐3β↓, 2,   HK2↓, 1,   lactateProd↓, 1,   e-lactateProd↓, 1,   LDHA↓, 2,   NADPH↓, 1,   PDK1 / PDPK1↓, 1,   PKM2↓, 3,   SIRT1↓, 1,   SIRT1↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

AIF↑, 1,   Apoptosis↓, 3,   Apoptosis↑, 30,   Bak↑, 1,   BAX↓, 1,   BAX↑, 16,   Bax:Bcl2↑, 8,   Bcl-2↓, 27,   Bcl-2↑, 1,   Bcl-xL↓, 14,   BID↓, 1,   Casp↑, 7,   Casp1↓, 1,   Casp3?, 1,   Casp3↑, 17,   cl‑Casp3↑, 3,   Casp7?, 1,   Casp7↑, 5,   cl‑Casp7↑, 1,   Casp8↑, 6,   cl‑Casp8↑, 1,   Casp9?, 1,   Casp9↓, 1,   Casp9↑, 13,   cl‑Casp9↑, 1,   Cyt‑c↑, 11,   DR5↑, 3,   FADD↑, 1,   Fas↑, 1,   IAP1↓, 5,   IAP2/BIRC3↓, 4,   IAP2/BIRC3↑, 1,   iNOS↓, 2,   Mcl-1↓, 2,   MDM2↓, 1,   p38↑, 6,   p‑p38↑, 2,   survivin↓, 19,   TRAIL↑, 2,   TumCD↑, 1,   XIAP↓, 12,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 13,   Akt↑, 2,   p‑Akt↓, 6,   AKT1↓, 1,   AMPKα↑, 2,   cMET↓, 1,   cSrc↓, 2,   EGFR↓, 1,   ERK↓, 7,   ERK↑, 1,   p‑ERK↓, 1,   IκB↓, 1,   JAK2↓, 6,   p‑JAK2↓, 1,   JNK↓, 1,   JNK↑, 3,   MAPK↓, 2,   MAPK↑, 3,   p‑MAPK↑, 2,   MEK↓, 1,   mTOR↓, 7,   p‑mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 13,   PI3K↑, 1,   p‑PI3K↓, 2,   PI3k/Akt/mTOR↓, 1,   PTEN↑, 10,   Raf↓, 1,   RAS↓, 1,   Sp1/3/4↓, 2,   c-Src↓, 1,   STAT3↓, 11,   p‑STAT3↓, 5,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   cJun↑, 2,   cMyc↓, 8,   DNMT1↓, 8,   DNMT3A↓, 2,   DNMTs↓, 1,   EZH2↓, 1,   FOXO↑, 2,   H4↑, 1,   ac‑H4↑, 1,   HDAC↓, 14,   HDAC1↓, 8,   HDAC2↓, 2,   HDAC3↓, 2,   HDAC4↓, 3,   miR-29b↑, 1,   miR-34a↑, 1,   Myc↓, 1,   tumCV↓, 12,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 1,   eIF2α↓, 1,   p‑eIF2α↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 2,   HSP70/HSPA5↓, 1,   HSP70/HSPA5↑, 2,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG7↑, 1,   Beclin-1/ATG6↑, 2,   LC3II↑, 1,   p62↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↑, 1,   DNAdam↓, 1,   DNAdam↑, 4,   G9a↓, 2,   hTERT/TERT↓, 2,   p16↑, 2,   P53↑, 19,   P53⇅, 1,   PARP↓, 1,   cl‑PARP↑, 13,   PCNA↓, 1,   Telomerase↓, 1,   UHRF1↓, 4,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 3,   CDK6↓, 1,   cycA1/CCNA1↓, 3,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 18,   CycD3↑, 1,   cycE/CCNE↓, 2,   E2Fs↓, 1,   GADD45A↑, 2,   Ki-67↓, 5,   P21↑, 19,   p27/CDKN1B↑, 6,   TumCCA↓, 1,   TumCCA↑, 24,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   EP2↓, 1,   EP4/PTGER4↓, 1,   Gli1↓, 1,   HH↓, 1,   Jun↓, 1,   Ki-67↓, 5,   NOTCH↓, 3,   Shh↓, 1,   TumCG↓, 4,   TumCP↓, 23,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   DLC1↑, 3,   E-cadherin↓, 1,   E-cadherin↑, 5,   EMT↓, 9,   FAK↓, 2,   ITGA5↓, 1,   MET↓, 1,   MMP2↓, 5,   MMP7↓, 2,   MMP9↓, 10,   MMPs↓, 3,   MUC4↓, 5,   N-cadherin↓, 4,   Rac1↓, 2,   Slug↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 2,   TGF-β↑, 1,   TumCI↓, 7,   TumCI↑, 1,   TumCMig↓, 7,   TumMeta↓, 11,   Twist↓, 8,   uPAR↓, 1,   Vim↓, 3,   Zeb1↓, 4,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 11,   angioG↑, 1,   Hif1a↓, 4,   NO↑, 1,   VEGF↓, 13,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   MMP↓, 10,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

B2M↓, 1,   cDC2↓, 1,   COX2/PTGS2↓, 14,   CXCL1↓, 1,   CXCR4↓, 3,   DR4↑, 1,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL2↑, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 5,   MCP1/CCL2↓, 2,   MyD88↓, 1,   NF-kB↓, 26,   NF-kB↑, 1,   p‑NF-kB↑, 1,   NK cell↑, 1,   NLRP3↓, 2,   p65↓, 3,   p‑p65↓, 2,   PD-L1↓, 4,   PGE1↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 6,   TRIF↓, 1,  

Protein Aggregation(tgid=19) ⓘ

PRNP↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   PPARγ↓, 2,   PPARγ↑, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen?, 1,   ChemoSen↓, 1,   ChemoSen↑, 18,   CompStab↑, 2,   CompStab↝, 2,   CYP1B1↑, 2,   Dose↝, 5,   eff↓, 13,   eff↑, 7,   eff↝, 4,   MDR1↓, 1,   RadioS↑, 5,   selectivity↑, 15,   Synergy↑, 9,   TET2↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AR↓, 2,   AST↓, 1,   B2M↓, 1,   BRCA1↑, 1,   creat↓, 1,   EGFR↓, 1,   EZH2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 1,   LDH↑, 1,   Maspin↑, 2,   Myc↓, 1,   PD-L1↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 9,   cardioP↑, 3,   chemoP↑, 6,   chemoPv↑, 4,   hepatoP↑, 11,   neuroP↑, 4,   RenoP↑, 4,   TumVol↓, 4,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 314

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 2,   antiOx↑, 22,   Catalase↑, 15,   GCLC↑, 1,   GPx↑, 8,   GPx4↑, 1,   GSH↑, 23,   GSH/GSSG↑, 1,   GSR↑, 2,   GSSG↓, 2,   GSTs↑, 3,   H2O2↓, 3,   HO-1↓, 1,   HO-1↑, 12,   Keap1↓, 1,   lipid-P↓, 13,   MDA↓, 14,   MPO↓, 1,   MPO↑, 1,   NOX4↓, 1,   NQO1↑, 3,   NRF2↓, 1,   NRF2↑, 15,   Prx↑, 1,   ROS↓, 35,   ROS⇅, 1,   SOD↑, 23,   SOD1↑, 3,   TAC↑, 3,   Thiols↑, 2,   VitC↑, 1,   VitE↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

SIRT3↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 2,   ALAT↓, 4,   LDL↓, 1,   LTB4↓, 1,   LTC4↓, 1,   NAD↑, 1,   NADPH↑, 1,   SIRT1↑, 3,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3,   ASC?, 1,   BAX↓, 3,   Bax:Bcl2↓, 1,   Bcl-2↑, 1,   Casp1?, 1,   Casp1↓, 1,   Casp3↓, 7,   cl‑Casp3↓, 1,   proCasp3↓, 1,   Casp7↓, 1,   iNOS↓, 3,   iNOS↑, 2,   p38↓, 1,   p‑p38↓, 1,   Pyro?, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   p‑Akt↓, 2,   p‑Akt↑, 1,   e-Akt↑, 1,   AMPKα↑, 1,   CREB↑, 1,   p‑CREB↑, 1,   ERK↑, 1,   e-ERK↑, 1,   IκB↑, 1,   JNK↑, 2,   MAPK↓, 1,   MAPK↑, 1,   p‑mTOR↓, 1,   PI3K↓, 1,   PI3K↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

p‑cJun↓, 1,   cMyc↓, 1,   FOXO↑, 1,   other↓, 1,   other↝, 1,   tumCV∅, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 1,   neuroG↑, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

mt-ATPase↑, 1,   MMP13↓, 2,   MMP7↓, 1,   MMP9↓, 1,   MMP9↑, 1,   MMPs↓, 1,   SLIT2↑, 1,   TGF-β↓, 4,   TumCI↓, 1,   TumCI∅, 1,   TumCMig∅, 1,   TXNIP↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 2,   CD31/PECAM-1↓, 2,   eNOS↑, 1,   Hif1a↑, 2,   LOX1↓, 1,   NO↓, 4,   NO↑, 1,   VEGF↓, 2,   VEGF↑, 2,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 2,   MMP↑, 5,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 11,   CXCc↓, 1,   Eos↓, 5,   IFN-γ↓, 2,   IFN-γ↑, 4,   IFN-γ∅, 1,   IgE↓, 3,   IgG1↓, 1,   IL10↑, 3,   IL10∅, 1,   IL12↓, 3,   IL13↓, 2,   IL17↓, 1,   IL17∅, 1,   IL18↓, 1,   IL1β↓, 16,   IL4↓, 4,   IL4∅, 1,   IL5↓, 3,   IL6↓, 7,   Inflam↓, 28,   IP-10/CXCL-10↓, 1,   IRF3↓, 4,   MCP1/CCL2↓, 2,   MyD88↓, 3,   NF-kB↓, 17,   NLRP3↓, 2,   PGE2↓, 4,   Th2↓, 2,   TLR1↓, 1,   TLR2↓, 4,   TLR4↓, 4,   TNF-α↓, 14,   TRIF↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

Ach↑, 3,   AChE↓, 8,   AChE↝, 1,   BDNF↑, 1,   BDNF∅, 1,   ChAT↑, 1,   GABA↑, 1,   TrkB↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 8,   BACE/β-secretase↓, 1,   p‑tau↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

GR↑, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 4,   BioAv↝, 2,   CompStab↑, 1,   Dose↝, 3,   eff↓, 1,   eff↑, 7,   GSTA1↓, 1,   GSTA1↑, 4,   Half-Life↝, 2,   MRP↓, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 4,   ALP↓, 1,   AST↓, 4,   BUN↓, 1,   creat↓, 1,   CRP↓, 3,   FEV1↑, 2,   IL6↓, 7,   LDH↓, 2,   PEF↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AirwayM↓, 1,   AntiAge↑, 2,   antiAll?, 1,   antiAll↑, 13,   AntiCan↑, 2,   cardioP↑, 8,   chemoP↑, 1,   chemoPv↑, 1,   cognitive↑, 11,   GFR↑, 1,   hepatoP↑, 10,   memory↑, 10,   motorD↑, 2,   neuroP↑, 17,   OS↑, 2,   radioP↑, 6,   RenoP↑, 10,   toxicity↓, 3,   toxicity∅, 1,   Weight∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 1,   AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 202

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page